Respigen is intended to help patients manage chronic respiratory conditions that cause persistent discomfort and limit daily activities. It is primarily used for the long-term, daily supportive care of Chronic Obstructive Pulmonary Disease (COPD). The medication helps address the key symptoms of COPD, including shortness of breath, difficulty breathing, and recurrent wheezing. By assisting in the maintenance of more open airways, Respigen contributes to better functional capacity and may support a higher overall quality of life.

This medication offers an important part of a long-term treatment plan to stabilize symptoms and prevent the worsening of episodes.

---

Quick Fact: Relief for Shortness of Breath

Regulatory References

1. NIH MedlinePlus COPD guidance

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adults and adolescents (typically 12 years and older) with reversible obstructive airway disease.
• Children aged 4 years and older with reversible obstructive airway disease.

Populations for whom use is not recommended (if applicable):

• The pediatric population under 4 years of age (safety and efficacy are not established).
• Nursing mothers (breastfeeding), unless the expected benefits are judged to outweigh the potential risk to the infant.

Populations for whom use is contraindicated:

• Patients with known hypersensitivity to the active substance Salbutamol or to any of the product's excipients.
• Use to arrest uncomplicated premature labor or threatened abortion (for non-intravenous formulations).

Condition-specific eligibility rules (Use with Caution):

• Patients with hyperthyroidism (thyrotoxicosis) or uncontrolled diabetes mellitus.
• Patients with severe cardiovascular disorders, including coronary insufficiency, tachyarrhythmias, or hypertension.

Pregnancy and lactation eligibility status (if explicitly documented):

• Pregnancy: Use should only be considered if the expected benefit to the mother is greater than any possible risk to the fetus.
• Lactation: Use is generally not recommended unless the benefits outweigh the potential risk.

Eligibility Classifications (High-Level)

Classification	Example Regulatory Context
Contraindicated	Hypersensitivity, use in threatened abortion.
Caution/Restricted	Cardiovascular disorders, hyperthyroidism.
Not Established	Pediatric patients under 4 years of age.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine by establishing clear contraindications (absolute prohibitions, such as hypersensitivity) and specific age thresholds (ge 4 years). Eligibility is further restricted by cautionary use statements for pre-existing conditions like cardiovascular disease, hyperthyroidism, and diabetes, which necessitate careful monitoring. The status of use in pregnancy and lactation is defined as conditional, requiring the expected benefit to justify the potential risk, as documented in official government prescribing information.

Interactions with other medicines and products

Co-administration of Respigen with certain medicinal products requires caution due to potential drug-drug interactions, which are largely based on pharmacodynamic effects.

Documented Interacting Product Categories

Product Category	Example Medicines Listed	Interaction Constraint/Requirement
Beta-blockers	Bisoprolol, Propranolol	Should generally be avoided; they can antagonize the effect of Respigen. Non-selective beta-blockers must be used only after a careful assessment of risks versus benefits.
Diuretics	Bendroflumethiazide, Furosemide	Increased risk of hypokalaemia (low potassium level in the blood). Monitoring of serum potassium levels is advised.
Xanthine Derivatives	Theophylline, Aminophylline	Increased risk of hypokalaemia. Monitoring of serum potassium levels is advised.
Steroids	Prednisolone, other Corticosteroids	May potentiate the risk of hypokalaemia. Monitoring of serum potassium levels is advised.
Antidepressants	(Specific types not detailed)	Potential for altered effects or increased chance of certain side effects. Professional consultation is advised for concomitant use.

Specific Interaction Constraints

The most clinically significant interactions center on the risk of hypokalaemia, which may be exacerbated when Respigen is used concurrently with diuretics, xanthine derivatives, or steroids. This is particularly relevant in the context of acute severe asthma and low oxygen levels, where serum potassium levels are officially recommended to be monitored. The use of non-cardioselective beta-blocking agents is restricted because they can diminish or completely block the action of Respigen.

Respigen, which contains the active ingredient salbutamol, acts as a selective short-acting beta2-adrenoceptor agonist (SABA). Its pharmacodynamic mechanism is initiated by specific interaction with target receptor systems located primarily in the bronchial smooth muscle.

---

beta2-Receptor Mediated Signaling

Respigen works by directly binding to and activating the beta2-adrenoceptors on the cell surface. This interaction falls within the mechanistic domain of receptor-mediated signaling, where the exogenous agonist initiates a response cascade normally triggered by endogenous catecholamines.

---

Modulation of Bronchial Smooth Muscle Tone

The activation of beta2-adrenoceptors triggers the intracellular mechanistic cascade involving the enzyme adenylyl cyclase. This action increases the concentration of cyclic adenosine monophosphate (cAMP) within the smooth muscle cells. Elevated cAMP levels reduce intracellular calcium concentration, which ultimately leads to the relaxation of the bronchial smooth muscle. This molecular sequence directly modulates basal contractility signaling at the system level.

Instructions for Use

Respigen is administered by the oral inhaled route only using a pressurized metered-dose inhaler (MDI). Detailed procedural steps are mandatory for correct dosage delivery and device operation.

Administration Component	Details
Dosing Schedule	Adults and Children 4 years and older for acute symptoms or prevention of exercise-induced symptoms: 2 inhalations every 4 to 6 hours. One inhalation every 4 hours may be sufficient for some patients. More frequent use is not recommended.
Exercise Prevention	Administer 2 inhalations 15 to 30 minutes before exercise.
Maximum Frequency	Do not take more frequent administration or a greater number of inhalations than prescribed. For certain products, the maximum limit is 8 puffs in a 24-hour period.
Priming	The inhaler must be primed before first use, or if it has not been used for more than two weeks, or if it has been dropped. Priming typically involves releasing a set number of sprays (e.g., four) into the air, shaking well before each spray.
Inhalation Technique	Shake the inhaler well before each use. After breathing out completely, seal the lips around the mouthpiece, and begin to breathe in slowly and deeply while pressing down on the canister to release the spray. Hold the breath for up to 10 seconds, and then breathe out slowly. Wait 1 minute before taking a second puff, if prescribed.
Cleaning	The plastic actuator (mouthpiece) must be washed with warm running water and air-dried thoroughly at least once a week to prevent blockage and ensure proper dosing.

This structured approach defines the exact quantity, time interval, and method for administration, which is essential to ensure consistent use of the medicine.

Research Evidence / Overview of Studies for Respigen

---

1. Evidence for Rapid Relief of Acute Breathing Distress (Bronchospasm)

The primary body of research for Respigen (Salbutamol) consists of extensive short-term Randomized Controlled Trials (RCTs) and numerous systematic reviews. These studies were conducted during periods of increased symptom activity and focused on research involving conditions associated with acute or disruptive episodes, such as sudden airway tightening. Researchers used these trials to examine outcomes related to physical discomfort and outcomes describing episodic or acute changes, such as the time needed to track changes in airflow measures.

Studies consistently reported initial measurements of a change in airflow over defined time intervals. The trials also described patterns in clinical scoring systems, which were used to monitor outcomes related to symptom intensity like wheezing and difficulty breathing. Researchers monitored outcomes linked to clinical course, such as whether the study findings described patterns related to hospitalization rates or the length of time patients stayed in the emergency department.

The evidence focuses strictly on the acute clinical phase and, consequently, long-term outcomes are not well characterized. Additionally, research is ongoing to explore potential patterns where frequent use may be associated with a change in the stability of the medicine’s measured effect, sometimes referred to as tolerance development.

---

2. Evidence for Chronic Management of Chronic Obstructive Pulmonary Disease (COPD)

Research for its research involving the chronic condition of COPD primarily involves intermediate-to-long-term RCTs and observational studies that have tracked patient populations over many months. This research examined outcomes related to systemic or functional imbalance in patients with a condition marked by functional limitations. The studies explored how the medicine was observed in patients who were simultaneously using other types of daily maintenance inhalers; the study designs often did not isolate the independent effects of this medicine alone.

Findings indicate that data show patterns related to airflow measurements over time in these stable patient groups. Furthermore, the research explored outcomes describing episodic or acute changes, such as the rate at which patients experienced COPD exacerbations (flare-ups). Reported findings regarding certain outcomes, such as health-related quality of life assessments, were described as mixed or variable across systematic reviews.

---

3. Long-Term Studies and Durability of Response

Studies specifically explored the patterns observed when this medication was evaluated in trials lasting several months to a year, particularly in patients with COPD. This research examined the duration of its observed effects and explored changes in patient symptoms over time. These trials help show what has been observed so far regarding how symptoms evolved in the observed populations during extended study periods. Research in this area examined whether consistent, repeated use was associated with any change in the observed patterns of response.

---

4. Evidence in Specific Patient Populations

The body of research includes dedicated studies where the medicine was evaluated in distinct patient groups. Children were studied for acute symptom relief using endpoints that differed by age group; older adults were observed in cohorts for both acute and chronic conditions. The findings apply only to the populations studied; data for certain groups remain insufficient, meaning subgroup findings are uncertain.

---

5. What is Still Uncertain About the Research Base

The primary limitations stem from the follow-up durations were limited in many acute studies, and the complexity of its role in long-term disease management. In chronic conditions, the fact that patients often receive multiple treatments means that the research does not determine whether an individual will respond similarly to the medicine alone, as the study results reflect the specific conditions under which they were conducted (i.e., alongside other therapies). Furthermore, research focusing on certain nuanced outcomes, such as patterns related to tolerance development, is still emerging, and certainty remains low regarding the generalizability of these findings.

Key Studies & References Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (GOLD) 2024 Report

Common questions about Respigen (FAQ)

---

Q: What should I do if I miss a dose?

Official dosing guidelines focus on taking Respigen at the correct interval, typically every 4 to 6 hours for acute symptoms, and emphasize not to exceed the prescribed frequency or total daily number of inhalations. Specific instructions for managing a 'missed dose' are not detailed in regulatory documents. Regulatory guidelines emphasize adhering to the prescribed time intervals and maximum daily limits. Patients should consult their prescribing health professional for guidance on managing a missed dose.

---

Q: What is the physical size/volume of the inhaler (e.g., 200 puffs)?

Respigen is supplied as a pressurized metered-dose inhaler (pMDI) canister. The official product information specifies that the inhaler typically contains a certain number of doses, or actuations, such as 60 or 200 metered inhalations, which is listed on the packaging. This number represents the total available puffs in the canister.

---

Q: Do non-selective beta-blockers need to be completely stopped if I use Respigen?

Regulatory information indicates that non-selective beta-blocking agents, like propranolol, should generally be avoided alongside Respigen. These medicines can reduce or completely block the effect of Respigen. The use of these two types of drugs together should be based on a careful assessment by a healthcare professional, as stated in the prescribing information.

---

Q: I have a heart condition; can I use this drug safely?

Official warnings state that Respigen should be used with caution if you have certain heart conditions, such as high blood pressure, heart rhythm problems (cardiac arrhythmias), or coronary artery disease. Patients with pre-existing heart conditions should monitor for symptoms like chest pain or worsening heart disease, and should discuss any concerns with a healthcare professional before use.

---

Q: What is the shelf life of the medicine once the foil pouch is opened?

Regulatory documents state that the inhaler has a shelf life up until the expiry date printed on the packaging, provided it is stored correctly. However, once the sealed foil pouch is opened or the inhaler is first used, official patient instructions usually recommend discarding the canister after a specific time period (e.g., 12 months), or when the dose counter reaches zero, whichever comes first, to ensure the drug meets its specified quality and potency.

---

Q: Does the metal canister float or sink in water when the dose count is low?

Official instructions for Respigen, like other metered-dose inhalers, generally note that the water float test is not a reliable method for tracking remaining doses. This test may provide inaccurate results. Regulatory information recommends using the dose counter on the device or carefully tracking your daily puffs to know when the inhaler is nearing empty.

The official regulatory guidelines for Respigen (Salbutamol pMDI) define mandatory storage and disposal rules based on the medicine's stability and the safety of the pressurized canister.

Storage Requirements

Respigen must be stored at room temperature, typically below 25 C or 30 C. It is crucial to protect the inhaler from freezing, refrigeration, direct heat, and sunlight. The pressurized container must not be exposed to temperatures exceeding 50 C to prevent rupture, and must be kept in its original outer packaging when not in use. Stability is guaranteed until the expiry date if stored under these conditions.

Handling and Disposal

Always keep Respigen out of the sight and reach of children. The used or unused canister must not be pierced, broken, or incinerated. Disposal must be completed in accordance with local requirements for medicinal waste, often requiring return to a pharmacy, to ensure the safe handling of the residual propellant gases.